Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder

Christine L. Miller*, Ida C. Llenos, Mary Cwik, John Walkup, Serge Weis

*Corresponding author for this work

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Increased concentrations of kynurenine pathway metabolites have been reported by several groups for disorders involving psychosis, including schizophrenia and bipolar disorder. To identify components of the pathway that may be relevant as biomarkers or may underlie the etiology of psychosis, it is essential to characterize the extent of kynurenine pathway activation and to investigate known regulators of one of the key kynurenine-producing enzymes, tryptophan 2,3-dioxygenase (TDO2), previously shown in this laboratory to be increased commensurate with kynurenine in postmortem anterior cingulate brain tissue from individuals with schizophrenia. Using this same anterior cingulate sample set from individuals with schizophrenia, bipolar disorder, depression and controls (N = 12-14 per group), we measured the precursor of kynurenine and two downstream products. The precursor, tryptophan, was significantly increased only in the schizophrenia group (1.54-fold the mean control value, p = 0.02), and through substrate-induced activation, may be one cause of the increased kynurenine and kynurenine metabolites. This finding for tryptophan differs from some, but not all, previous reports and methodological reasons for the discrepancies are discussed. A product of kynurenine metabolism, 3-OH-anthranilic acid was also significantly increased only in the schizophrenia group (1.68-fold the mean control value, p = 0.03). 3-OH-anthranilic acid is a reactive species with cytotoxic properties, although the threshold for such effects is not known for neurons. Analysis of major pre- and post-mortem variables showed that none were confounding for these between-group experimental comparisons. Nicotinamide, a pathway end product, did not differ between groups but was associated with cause of death (suicide) within the bipolar group (p = 0.03).

Original languageEnglish (US)
Pages (from-to)1297-1303
Number of pages7
JournalNeurochemistry International
Volume52
Issue number6
DOIs
StatePublished - May 1 2008

Fingerprint

Kynurenine
Bipolar Disorder
Schizophrenia
Gyrus Cinguli
Tryptophan
Psychotic Disorders
Tryptophan Oxygenase
Niacinamide
Suicide
Cause of Death
Biomarkers
Neurons
Brain

Keywords

  • 3-Hydroxy-anthranilic acid
  • 3-OH-anthranilate
  • HPLC
  • Metabolites
  • Nicotinamide
  • Psychosis
  • Suicide
  • Tryptophan

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Cell Biology

Cite this

Miller, Christine L. ; Llenos, Ida C. ; Cwik, Mary ; Walkup, John ; Weis, Serge. / Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. In: Neurochemistry International. 2008 ; Vol. 52, No. 6. pp. 1297-1303.
@article{02ee0e79535d4c5fa0a018d9b6908f82,
title = "Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder",
abstract = "Increased concentrations of kynurenine pathway metabolites have been reported by several groups for disorders involving psychosis, including schizophrenia and bipolar disorder. To identify components of the pathway that may be relevant as biomarkers or may underlie the etiology of psychosis, it is essential to characterize the extent of kynurenine pathway activation and to investigate known regulators of one of the key kynurenine-producing enzymes, tryptophan 2,3-dioxygenase (TDO2), previously shown in this laboratory to be increased commensurate with kynurenine in postmortem anterior cingulate brain tissue from individuals with schizophrenia. Using this same anterior cingulate sample set from individuals with schizophrenia, bipolar disorder, depression and controls (N = 12-14 per group), we measured the precursor of kynurenine and two downstream products. The precursor, tryptophan, was significantly increased only in the schizophrenia group (1.54-fold the mean control value, p = 0.02), and through substrate-induced activation, may be one cause of the increased kynurenine and kynurenine metabolites. This finding for tryptophan differs from some, but not all, previous reports and methodological reasons for the discrepancies are discussed. A product of kynurenine metabolism, 3-OH-anthranilic acid was also significantly increased only in the schizophrenia group (1.68-fold the mean control value, p = 0.03). 3-OH-anthranilic acid is a reactive species with cytotoxic properties, although the threshold for such effects is not known for neurons. Analysis of major pre- and post-mortem variables showed that none were confounding for these between-group experimental comparisons. Nicotinamide, a pathway end product, did not differ between groups but was associated with cause of death (suicide) within the bipolar group (p = 0.03).",
keywords = "3-Hydroxy-anthranilic acid, 3-OH-anthranilate, HPLC, Metabolites, Nicotinamide, Psychosis, Suicide, Tryptophan",
author = "Miller, {Christine L.} and Llenos, {Ida C.} and Mary Cwik and John Walkup and Serge Weis",
year = "2008",
month = "5",
day = "1",
doi = "10.1016/j.neuint.2008.01.013",
language = "English (US)",
volume = "52",
pages = "1297--1303",
journal = "Neurochemistry International",
issn = "0197-0186",
publisher = "Elsevier Limited",
number = "6",

}

Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder. / Miller, Christine L.; Llenos, Ida C.; Cwik, Mary; Walkup, John; Weis, Serge.

In: Neurochemistry International, Vol. 52, No. 6, 01.05.2008, p. 1297-1303.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Alterations in kynurenine precursor and product levels in schizophrenia and bipolar disorder

AU - Miller, Christine L.

AU - Llenos, Ida C.

AU - Cwik, Mary

AU - Walkup, John

AU - Weis, Serge

PY - 2008/5/1

Y1 - 2008/5/1

N2 - Increased concentrations of kynurenine pathway metabolites have been reported by several groups for disorders involving psychosis, including schizophrenia and bipolar disorder. To identify components of the pathway that may be relevant as biomarkers or may underlie the etiology of psychosis, it is essential to characterize the extent of kynurenine pathway activation and to investigate known regulators of one of the key kynurenine-producing enzymes, tryptophan 2,3-dioxygenase (TDO2), previously shown in this laboratory to be increased commensurate with kynurenine in postmortem anterior cingulate brain tissue from individuals with schizophrenia. Using this same anterior cingulate sample set from individuals with schizophrenia, bipolar disorder, depression and controls (N = 12-14 per group), we measured the precursor of kynurenine and two downstream products. The precursor, tryptophan, was significantly increased only in the schizophrenia group (1.54-fold the mean control value, p = 0.02), and through substrate-induced activation, may be one cause of the increased kynurenine and kynurenine metabolites. This finding for tryptophan differs from some, but not all, previous reports and methodological reasons for the discrepancies are discussed. A product of kynurenine metabolism, 3-OH-anthranilic acid was also significantly increased only in the schizophrenia group (1.68-fold the mean control value, p = 0.03). 3-OH-anthranilic acid is a reactive species with cytotoxic properties, although the threshold for such effects is not known for neurons. Analysis of major pre- and post-mortem variables showed that none were confounding for these between-group experimental comparisons. Nicotinamide, a pathway end product, did not differ between groups but was associated with cause of death (suicide) within the bipolar group (p = 0.03).

AB - Increased concentrations of kynurenine pathway metabolites have been reported by several groups for disorders involving psychosis, including schizophrenia and bipolar disorder. To identify components of the pathway that may be relevant as biomarkers or may underlie the etiology of psychosis, it is essential to characterize the extent of kynurenine pathway activation and to investigate known regulators of one of the key kynurenine-producing enzymes, tryptophan 2,3-dioxygenase (TDO2), previously shown in this laboratory to be increased commensurate with kynurenine in postmortem anterior cingulate brain tissue from individuals with schizophrenia. Using this same anterior cingulate sample set from individuals with schizophrenia, bipolar disorder, depression and controls (N = 12-14 per group), we measured the precursor of kynurenine and two downstream products. The precursor, tryptophan, was significantly increased only in the schizophrenia group (1.54-fold the mean control value, p = 0.02), and through substrate-induced activation, may be one cause of the increased kynurenine and kynurenine metabolites. This finding for tryptophan differs from some, but not all, previous reports and methodological reasons for the discrepancies are discussed. A product of kynurenine metabolism, 3-OH-anthranilic acid was also significantly increased only in the schizophrenia group (1.68-fold the mean control value, p = 0.03). 3-OH-anthranilic acid is a reactive species with cytotoxic properties, although the threshold for such effects is not known for neurons. Analysis of major pre- and post-mortem variables showed that none were confounding for these between-group experimental comparisons. Nicotinamide, a pathway end product, did not differ between groups but was associated with cause of death (suicide) within the bipolar group (p = 0.03).

KW - 3-Hydroxy-anthranilic acid

KW - 3-OH-anthranilate

KW - HPLC

KW - Metabolites

KW - Nicotinamide

KW - Psychosis

KW - Suicide

KW - Tryptophan

UR - http://www.scopus.com/inward/record.url?scp=40949098991&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40949098991&partnerID=8YFLogxK

U2 - 10.1016/j.neuint.2008.01.013

DO - 10.1016/j.neuint.2008.01.013

M3 - Article

VL - 52

SP - 1297

EP - 1303

JO - Neurochemistry International

JF - Neurochemistry International

SN - 0197-0186

IS - 6

ER -